Metabolic hepatic steatosis: what the diabetologist needs to know

Authors

  • Kenneth Cusi University of Florida, Florida, United States

Keywords:

metabolic dysfunction–associated steatotic liver disease, diabetes

Abstract

MASLD and its more severe form called MASH, can promote the development of cirrhosis, hepatocellular carcinoma, cardiovascular disease, and type 2 diabetes. The diagnosis is based on the early screening with FIB-4 and elastography (Fibroscan). Lifestyle are key to success and bariatric surgery is useful when properly indicated. Pharmacological treatment for obesity and type 2 diabetes can avoid disease progression, especially treatment with pioglitazone, glucagon-like peptide 1 receptor agonists, and tirzepatide.

Author Biography

Kenneth Cusi, University of Florida, Florida, United States

Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine

References

I. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022;10:284-296.

II. Nogueira JP, Cusi K. Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: From bench to patient care. Diabetes Spectr 2024;37:20-28.

III. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of NAFLD in primary

care and endocrinology clinical settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice 2022;28:528-562.

IV. Genua I, Cusi K. Pharmacological approaches to nonalcoholic fatty liver disease: Current and future therapies. Diabetes Spectrum 2024;37:48-58.

Downloads

Published

2024-10-01

How to Cite

Cusi, K. (2024). Metabolic hepatic steatosis: what the diabetologist needs to know. Journal of the Argentine Society of Diabetes, 58(3Sup), 58–59. Retrieved from https://revistasad.com/index.php/diabetes/article/view/1076

Issue

Vol. 58 No. 3Sup (2024): September-December

Section

Conferences part 3

License

Copyright (c) 2024 on behalf of the authors. Reproduction rights: Argentine Society of Diabetes

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.